



25th International Conference on Antiviral Research (ICAR)

Preliminary Scientific Program

Monday, April 16, 2012

- Afternoon **Interactive Workshop: Drug Discovery and Development 101**
Raj Kalkeri, PhD, Vertex Pharmaceuticals, USA: *"HTS and Drug Development"*
Sina Bavari, PhD, United States Army Medical Research Institute of Infectious Diseases, USA: *"Animal Models and Drug Development"*
Isabel Najera, PhD, Roche, USA: *"Resistance Testing and Drug Development"*

- Evening **Keynote Address and Welcoming Reception**
Keynote Speaker: Hiroaki Mitsuya, NCI, USA and Kumamoto University School of Medicine, Japan: *"Structure-Guided Development of AIDS Therapeutics: Successes, Challenges, and Opportunities"*

Lecture

Erik De Clercq, Rega Institute for Medical Research, Belgium: Success and Failures in an Antiviral Drug Development: A Personal Account

Tuesday, April 17, 2012

- Morning **Oral Session I: Mini-Symposium: "Therapies for Infections Endemic to Asia"**
Kouichi Morita, Nagasaki University, Japan: *Japanese Encephalitis Virus (JEV)*
Jun-ichi Fujisawa, Kansai Medical University, Japan: *HTLV-1*
Takaji Wakita, NIH, Japan: *Hepatitis C Virus (HCV)*
Pei Yong Shi, Novartis, Singapore: *Dengue virus*
Richard Block, PhD, Hepatitis B Foundation and Drexel University, USA: *Hepatitis B Virus*
TBD: *Influenza Virus*

- Afternoon **Gertrude Elion Memorial Award Lecture**

Oral Session II: Hepatitis Viruses
Plenary Speaker

Poster Session I: Retroviruses, Hepatitis Viruses, Respiratory Viruses and Antiviral Methods

Wednesday, April 18, 2012

- Morning **Oral Session III: Respiratory and Emerging Viruses**
Plenary Lecture: **William Prusoff Young Investigator Award Lecture**

- Afternoon **Clinical Symposium**
Invited Speakers: TBD

Poster Session II: Herpes Viruses, Poxviruses, Other Antivirals. Medicinal, Chemistry and Topical Microbicides

Thursday, April 19, 2012

- Morning **Oral Session IV: Building a Better Clinical Candidate: Issues, Strategies and Tools**
Reza Oleyai, PhD, Gilead Sciences, USA: *"Role of Prodrug Design in Drug Discovery and Lead Optimization"*
Robert Zahler, PhD, PharmD Consulting, USA: *"Reactive Metabolites in Drug Discovery: Implications, Anticipation and Management"*
Paul Scola, PhD, Bristol Myers Squibb, USA: *"The Discovery of Asunaprevir (BMS-650032): A Protease Inhibitor for the Treatment of Hepatitis C Virus"*
Avinash Phadka, PhD, Achillion, USA: *"HCV-Protease Inhibitors: Discovery of ACH1625 and ACH2684"*
Dominique Surleraux, PhD, Idenix, USA: *"IDX184 and Other Nucleotide Prodrug Candidates or the Therapy of HCV"*

- Afternoon **Oral Session V: Retroviruses and Herpes Viruses**
Plenary Speaker: **Joachim Hauber, PhD**, Heinrich Pette Institute, Germany: *"Towards virus eradication: Excision of HIV-1 proviral DNA using LTR-specific recombinase"*

Shot Gun Poster Session for Young Investigators:

Closing
Banquet